Response Genetics, Inc. (RGDX) Reports Wider Q2 Loss of $0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Response Genetics, Inc. Announces Second Quarter 2014 Financial Results
August 14, 2014 7:00 AM EDTLOS ANGELES, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2014.
Second Quarter 2014 Highlights:
Record ResponseDX® revenues increase 18% over Q2 2013 and 11% over Q1 2014 Volume increases 16% over Q1 2014 Gross margins increase to 40% Operating loss decreases 11% from Q1 2014Total revenue for the second quarter ended June 30, 2014 was $4.3 million compared to... More
